Basilea announces pediatric fosmanogepix data for IDWeek 2026

By Public Technologies
  • Basilea Pharmaceutica will present new fosmanogepix, isavuconazole and ceftobiprole data at IDWeek 2026, October 21-24, in Washington, D.C.
  • Phase 3 antifungal fosmanogepix presentations on October 23 will cover pediatric expanded-access experience in invasive mold infections and manogepix activity against Candida auris.
  • Other research will examine isavuconazole safety and treatment use, alongside ceftobiprole dosing and evidence supporting pediatric use.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Basilea Pharmaceutica AG published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610200115PRIMZONEFULLFEED1001278790) on October 20, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk